United States: Amgen v. Sandoz The Supreme Courts First Biosimilars Ruling

In a unanimous decision issued on June 12, 2017, the Supreme Court for the first time interpreted key provisions of the 2010 Biologics Price Competition and Innovation Act ("BPCIA"). See Sandoz Inc. v. Amgen Inc., No. 15-1195 (U.S. June 12, 2017). The Court's decision grants more flexibility to biosimilar companies and filers of abbreviated Biologics License Applications ("aBLAs"), holding that (1) a reference product sponsor is not entitled to injunctive relief under federal law for an applicant's refusal to provide a copy of its aBLA and manufacturing information during the information exchange period contemplated by the BPCIA, and (2) an applicant may provide statutory 180-day pre-launch notice of commercial marketing before its proposed biosimilar product is licensed by FDA. An overview of the parties' oral arguments before the Court on these issues can be found here.

The Federal Circuit Holdings on Appeal to the Supreme Court

The Amgen v. Sandoz proceedings arose out of Sandoz's filing an aBLA with FDA to market a biosimilar version of Amgen's approved Neupogen (filgrastim) biologic. As we previously discussed, the Federal Circuit opinion below had held that:

  1. aBLA applicants do not violate the BPCIA by "opting out" of the BPCIA's "patent dance" information exchange procedures and choosing not to provide a reference product sponsor, like Amgen, with a copy of their aBLAs and manufacturing information as described in 42 U.S.C. § 262(l)(2)(A); and
  2. aBLA applicants may not provide the reference product sponsor with 180-day pre-launch notice of commercial marketing pursuant to 42 U.S.C. § 262(l)(8)(A) until after FDA approves the biosimilar product.

The Supreme Court affirmed the Federal Circuit on the first issue, albeit on different grounds, and reversed on the second issue.

The BPCIA "Patent Dance" Information Exchange is Optional, and a Biosimilar Manufacturer's Failure to Participate is Not a Violation of the BPCIA

The Supreme Court affirmed the Federal Circuit by holding that a reference product sponsor may not pursue an injunction under federal law if the aBLA applicant refuses to engage in the BPCIA's "patent dance" information exchange. Specifically at issue was § 262(l)(2)(A) of the BPCIA, which instructs that an aBLA applicant "shall provide to the reference product sponsor a copy of the [aBLA] application" and information describing the biosimilar product manufacturing processes.

Despite agreeing with the Federal Circuit's holding on this question, the Supreme Court took issue with the Federal Circuit's reasoning. An applicant's failure to comply with § 262(l)(2)(A), the Court held, is not an act of artificial infringement under 35 U.S.C. § 271(e)(4). Instead, such failure simply provides the reference product sponsor with a different and exclusive remedy under § 262(l)(9)(C). That section allows the sponsor to bring an immediate declaratory judgment action for patent infringement under § 271(e)(2)(C)(ii). No injunctive relief is permitted under the BPCIA for such an act. The Court also observed that in contrast with § 262(l)(2)(A), a different provision of the BPCIA, § 262(l)(1)(H), expressly allows for an injunctive remedy. Thus, the Court held, Congress clearly knew how to provide for injunctive relief in the event of an applicant's failure to follow BPCIA provisions, but deliberately chose not to provide such relief when an aBLA applicant fails to engage in the § 262(l)(2)(A) information exchange.

While the biosimilar applicant may refuse to participate in the § 262(l)(2)(A) information exchange without subjecting itself to an injunction, that refusal is not without consequence. For example, the reference product sponsor's ability to bring a declaratory judgment action under § 262(l)(9)(C) on "any patent that claims the biological product or a use of the biological product" is no longer limited to the applicant-controlled "list" of patents. The reference product sponsor, and not the biosimilar applicant, is thus more able to control the scope and timing of the ensuing patent litigation.

The Court remanded to the lower courts to determine whether failure to engage in the § 262(l)(2)(A) information exchange is "unlawful" under California's unfair competition law. The Court offered no opinion on that issue of state law, but did vacate the opinion below because it improperly considered only the BPCIA, rather than California law.

aBLA Applicants May Provide 180-day Notice of Commercial Marketing Before FDA Approves a Biosimilar Product

The Court also reversed the Federal Circuit by holding that an aBLA applicant need not wait until FDA actually licenses a biosimilar product before providing the reference product sponsor with the 180-day notice of commercial marketing required under § 262(l)(8)(A). Rejecting Amgen's proposed statutory construction, the Court based its holding on the fact that the plain language of § 262(l)(8)(A) imposes only a single timing requirement, namely to provide notice at least 180 days before first commercial marketing. Section 262(l)(8)(A) makes no reference to the date of FDA biosimilar licensing, the Court held, and thus does not require that notice only follow FDA approval. Once again, the Court pointed to language elsewhere in the BPCIA to establish that Congress knew how to impose such a requirement but deliberately chose not to in this case. For example, § 262(l)(8)(B) plainly allows a preliminary injunction suit after receiving notice and before first commercial marketing.

The Court recognized that policy considerations support arguments for and against requiring biosimilar approval before allowing the 180-day notice, but noted that even persuasive policy considerations must take a backseat to the BPCIA's "plain language" in this case.

Supreme Court Provides Some Clarity, But BPCIA Litigation Likely to Continue

The Supreme Court's ruling clarifies that aBLA applicants may completely refuse to engage in the BPCIA's "patent dance" information exchange, and need not wait for FDA approval of the biosimilar product before providing the reference product sponsor with 180-day notice of commercial marketing.

It remains to be seen how aBLA applicants and reference product sponsors will respond to the Court's ruling. The 180-day notice ruling, for example, will likely have a significant impact on the timing of the "second phase" of BPCIA litigation. For many biologic products, this means the first and second "phases" of BPCIA litigation may be effectively merged. But not all applicants may wish to engage in litigation on all of a sponsor's listed patents any earlier than necessary.

Moreover, as Justice Breyer's concurrence explains, even the issues resolved by the Court's ruling may not stay settled for good. Justice Breyer wrote separately to point out that FDA may, after "greater experience administering" the BPCIA, have authority to depart from or modify the Court's interpretation.

Stay tuned for further coverage of this and other BPCIA issues making their way through the courts.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.